Patents by Inventor Andrei Gudkov

Andrei Gudkov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9381225
    Abstract: The use of lipopeptides comprising variable groups defined as H or optionally substituted C6-C20 aliphatic and a peptide of one of the following amino acid sequences: GEESN (SEQ ID NO: 17), QGEESNDK (SEQ ID NO: 20), and VQGEESNDK (SEQ ID NO: 21). The use of the lipopeptides for activating Toll-like receptors (TLRs) in cells is described.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: July 5, 2016
    Assignees: CLEVELAND CLINIC FOUNDATION, CLEVELAND BIOLABS, INC.
    Inventors: Alexander Shakhov, Andrei Gudkov, Elena Feinstein
  • Patent number: 9376473
    Abstract: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: June 28, 2016
    Assignee: Cleveland BioLabs, Inc.
    Inventors: Anatoli Gleiberman, Lyudmila Burdelya, Andrei Gudkov
  • Publication number: 20150342927
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
    Type: Application
    Filed: June 4, 2015
    Publication date: December 3, 2015
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Publication number: 20150328284
    Abstract: Provided are compositions and methods for prophylaxis and/or therapy of dermal damage. The compositions and methods involve Toll like receptor (TLR) agonists that can inhibit the formation or accelerate healing of dermal damage, and/or inhibit inflammation at near the location of the dermal damage. The TLR agonists can be TLR2 and/or TLR5 agonists. The compositions and methods are suitable for prophylaxis and/or therapy of dermal damage caused by radiation, or non-radiation thermal injury such as burns caused by contact with heated surfaces or heated objects, light, and for disruptions in integument resulting in cuts, such as incisions, or punctures. The compositions can be used topically, subcutaneously or systemically. Articles of manufacture coated or impregnated with TLR agonist(s) are also provided.
    Type: Application
    Filed: April 2, 2013
    Publication date: November 19, 2015
    Inventors: Andrei GUDKOV, Lyudmila BURDELYA
  • Publication number: 20150306168
    Abstract: The use of lipopeptides as inducers of NF-?B for the protection of mammals from the effects of apoptosis is described.
    Type: Application
    Filed: March 6, 2015
    Publication date: October 29, 2015
    Inventors: Alexander Shakhov, Andrei Gudkov
  • Patent number: 9169207
    Abstract: The present invention relates to the treatment of breast cancer which is estrogen receptor positive (ER+) and/or human epidermal growth factor receptor 2 positive (HER2) and/or progesterone receptor positive (PR) and/or facilitates chromatin transcription positive (FACT+) with a curaxin, including curaxin 137. The present invention also pertains to a method of identifying a subject who has a breast cancer tumor and is likely to respond to treatment with a curaxin.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: October 27, 2015
    Assignee: Incuron, LLC
    Inventors: Andrei Gudkov, Katerina Gurova
  • Publication number: 20150285823
    Abstract: Provided is the discovery that dormant senescence prone cells (DSPCs) record an organism's exposure to genotoxic stress over the lifetime of the organism. The disclosure includes identifying DSPCs, using the amount of DSPCs to determine genotoxic dosage/dosimetry, and using these determinations in treatment and therapeutic approaches.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Andrei Gudkov, Katerina Leonova
  • Publication number: 20150272960
    Abstract: Pharmaceutical compositions including a Myc inhibitor are provided. Also provided are methods for treating cancer including administration of compounds that inhibit oncoprotein Myc.
    Type: Application
    Filed: October 14, 2013
    Publication date: October 1, 2015
    Inventors: Andrei Gudkov, Mikhail Nikiforov, Catherine Burkhart, Michelle Haber, Murray Norris
  • Patent number: 9108916
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: August 18, 2015
    Assignee: Incuron, LLC
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Publication number: 20150182587
    Abstract: The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin
    Type: Application
    Filed: March 11, 2015
    Publication date: July 2, 2015
    Inventors: Andrei Gudkov, Robert Fairchild
  • Patent number: 9006180
    Abstract: The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: April 14, 2015
    Assignees: Cleveland BioLabs, Inc., Cleveland Clinic Foundation
    Inventors: Andrei Gudkov, Robert Fairchild
  • Patent number: 9006183
    Abstract: The use of lipopeptides as inducers of NF-?B for the protection of mammals from the effects of apoptosis is described.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: April 14, 2015
    Assignees: Cleveland Clinic Foundation, Cleveland BioLabs, Inc.
    Inventors: Alexander Shakhov, Andrei Gudkov
  • Publication number: 20150064697
    Abstract: Provided is a disclosure of methods involving determining RNA transcripts transcribed from repeats of polynucleotide sequences, the transcription of which are normally repressed by a combination of functional p53 and DNA methylation, and methods of detecting interferon, and determining constitutive activation of an interferon type I response. The methods permit identification of cancerous or precancerous cells, can identify non-functional p53, and provide therapeutic and prophylactic approaches for cancer.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 5, 2015
    Inventors: Andrei Gudkov, Yekaterina Leonova
  • Publication number: 20150045406
    Abstract: The present invention relates to the treatment of breast cancer which is estrogen receptor positive (ER+) and/or human epidermal growth factor receptor 2 positive (HER2) and/or progesterone receptor positive (PR) and/or facilitates chromatin transcription positive (FACT+) with a curaxin, including curaxin 137. The present invention also pertains to a method of identifying a subject who has a breast cancer tumor and is likely to respond to treatment with a curaxin.
    Type: Application
    Filed: March 27, 2013
    Publication date: February 12, 2015
    Inventors: Andrei Gudkov, Katerina Gurova
  • Publication number: 20140303224
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
    Type: Application
    Filed: April 1, 2014
    Publication date: October 9, 2014
    Applicant: Incuron, LLC
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Publication number: 20140248260
    Abstract: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.
    Type: Application
    Filed: January 10, 2012
    Publication date: September 4, 2014
    Applicant: CLEVELAND BIOLABS, INC.
    Inventors: Anatoli Gleiberman, Lyudmila Burdelya, Andrei Gudkov
  • Publication number: 20140220037
    Abstract: The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin
    Type: Application
    Filed: November 22, 2013
    Publication date: August 7, 2014
    Applicants: Cleveland Clinic Foundation, Cleveland BioLabs, Inc.
    Inventors: Andrei Gudkov, Robert Fairchild
  • Patent number: 8765738
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: July 1, 2014
    Assignee: Incuron, LLC
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Publication number: 20140045750
    Abstract: The use of lipopeptides as inducers of NF-?B for the protection of mammals from the effects of apoptosis is described.
    Type: Application
    Filed: July 15, 2013
    Publication date: February 13, 2014
    Inventors: Alexander Shakhov, Andrei Gudkov
  • Patent number: 8618059
    Abstract: The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: December 31, 2013
    Assignees: Cleveland BioLabs, Inc., Cleveland Clinic Foundation
    Inventors: Andrei Gudkov, Robert Fairchild